Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Qyuns Therapeutics Co., Ltd. Class H ( (HK:2509) ) has provided an announcement.
Qyuns Therapeutics Co., Ltd. announced that its subsidiary, Jiangsu Cellularforce Biopharma Co., Ltd., has successfully passed the EU Qualified Person (QP) audit, meeting the EU GMP standards. This achievement marks a significant milestone in the company’s global expansion strategy, enabling its products to enter the EU market and strengthening its international market presence.
The most recent analyst rating on (HK:2509) stock is a Hold with a HK$32.00 price target. To see the full list of analyst forecasts on Qyuns Therapeutics Co., Ltd. Class H stock, see the HK:2509 Stock Forecast page.
More about Qyuns Therapeutics Co., Ltd. Class H
Qyuns Therapeutics Co., Ltd. is a joint stock company based in China, specializing in the development and commercialization of innovative biologics. Through its subsidiary, Jiangsu Cellularforce Biopharma Co., Ltd., the company offers comprehensive biologics CDMO services that meet international standards, including NMPA, FDA, and EMA. These services span the entire drug development process, from molecule design to commercial production, aiming to accelerate drug development and reduce costs.
Average Trading Volume: 851,747
Technical Sentiment Signal: Buy
For a thorough assessment of 2509 stock, go to TipRanks’ Stock Analysis page.
Disclaimer & DisclosureReport an Issue
